{"id":"shr-a2009-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL6068589","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SHR-A2009 is designed as a bispecific monoclonal antibody targeting immune checkpoint pathways to overcome tumor immune evasion. By engaging multiple immune regulatory pathways simultaneously, it aims to enhance T-cell activation and proliferation against cancer cells. This dual-targeting approach may provide superior efficacy compared to single-checkpoint inhibitors.","oneSentence":"SHR-A2009 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:27.255Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75813,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-A2009 monotherapy","genericName":"SHR-A2009 monotherapy","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-A2009 is a bispecific antibody that simultaneously engages two immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}